Moderna (MRNA) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Moderna’s latest COVID-19 mRNA vaccine, designed to combat the SARS-CoV-2 variant JN.1, has received a positive opinion from the EMA’s CHMP, which recommends it for the upcoming 2024-2025 vaccination season in the EU, pending final authorization. The vaccine is part of Moderna’s efforts to adapt to evolving variants, with approvals already in place for different formulations in Japan, Taiwan, the UK, and the US. This development is pivotal as it underscores Moderna’s commitment to combatting COVID-19 with updated vaccinations.
For further insights into MRNA stock, check out TipRanks’ Stock Analysis page.
